Health

CRISPR

$181.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$7.25 (-3.85%) Today
-$0.04 (-0.02%) As of 12:40 PM UTC after-hours

Why Robinhood?

You can buy or sell CRISPR and other stocks, options, and ETFs commission-free!

About CRSP

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland. The listed name for CRSP is CRISPR Therapeutics AG Common Shares.

CEO
Samarth Kulkarni
Employees
304
Headquarters
Zug, Zug
Founded
2014
Market Cap
13.49B
Price-Earnings Ratio
Dividend Yield
Average Volume
2.93M
High Today
$191.10
Low Today
$176.75
Open Price
$188.48
Volume
2.30M
52 Week High
$220.20
52 Week Low
$32.30

Collections

CRSP Earnings

-$1.32
-$0.08
$1.16
$2.40
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 10, Pre-Market

You May Also Like

ALC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure